These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 36578492)

  • 1. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
    Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
    Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort.
    Gamba A; Depascale R; Zanatta E; Ienna L; Cruciani C; Gatto M; Zen M; Doria A; Iaccarino L
    Clin Rheumatol; 2024 Oct; 43(10):3167-3174. PubMed ID: 39196499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
    Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
    J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
    Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
    Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of ischemic stroke in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.
    Zhen C; Wang Y; Wang H; Wang X
    Clin Rheumatol; 2021 Oct; 40(10):4101-4108. PubMed ID: 33934269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis.
    Mandel DE; Malemud CJ; Askari AD
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
    Moghadam-Kia S; Oddis CV; Aggarwal R
    Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
    de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
    Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
    Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
    Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
    Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
    J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
    Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
    Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From data to diagnosis: how machine learning is revolutionizing biomarker discovery in idiopathic inflammatory myopathies.
    McLeish E; Slater N; Mastaglia FL; Needham M; Coudert JD
    Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38243695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current diagnosis and treatment of polymyositis and dermatomyositis.
    Sasaki H; Kohsaka H
    Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
    Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
    Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
    Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
    Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of infliximab in treating idiopathic inflammatory myopathies: A review article.
    Ge Y; Li S; Chen F; He L; Li C; Lu X; Wang G
    Dermatol Ther; 2021 Jul; 34(4):e14976. PubMed ID: 33991036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients.
    Choi J; Nam SH; Lee JS; Ahn SM; Hong S; Kim YG; Lee CK; Kim J; Ghang B; Yoo B
    Clin Rheumatol; 2024 Nov; 43(11):3379-3387. PubMed ID: 39352438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.